Tower Research Capital (TRC)’s Psyence Biomedical PBM Stock Holding History

Tower Research Capital (TRC)’s Portfolio PBM Stock Details PBM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-40	Closed	-$4.21K	–	5875
2024 Q4	$4.21K	Buy	40 +31	+344%	+$7.39K	﹤0.01%	4495
2024 Q3	$3.44K	Buy	+9	New	+$12.2K	﹤0.01%	4847

Other funds holding PBM

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

SFFS

Stonehage Fleming Financial Services St. Helier, Jersey $2.75B AUM 13.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tower Research Capital (TRC)'s PBM Position: Q1 2025 in Review

Tower Research Capital (TRC) sold out of Psyence Biomedical (PBM) in Q1 2025, closing a stake of 40 shares — an estimated $4.21K sold.

Tower Research Capital (TRC) first reported a position in PBM in Q3 2024 and held it in 2 quarters. The position peaked at $4.21K in Q4 2024. 8 funds tracked by Wall St. Rank hold PBM as of Q1 2025.

Tower Research Capital (TRC) reported no remaining Psyence Biomedical position as of Q1 2025 after selling out during the quarter.
Tower Research Capital (TRC) sold 40 Psyence Biomedical shares in Q1 2025, an estimated $4.21K.
Tower Research Capital (TRC) first reported a position in Psyence Biomedical in Q3 2024 and held it in 2 quarters.
Tower Research Capital (TRC)'s Psyence Biomedical position peaked at $4.21K in Q4 2024.
8 funds tracked by Wall St. Rank held Psyence Biomedical as of Q1 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.